Last updated: February 20, 2026
Has the development or approval status of clorazepate dipotassium changed recently?
Clorazepate dipotassium has largely exited new clinical development phases and is no longer under active investigation for new indications. The drug, a benzodiazepine, was initially approved by the FDA in 1969 for short-term management of anxiety, and later approved in 1985 for seizure control. Its dosage forms include tablets and oral solutions. No recent clinical trials or regulatory submissions have been announced, indicating a shift toward generic use and limited R&D activity.
What is the current state of clinical trials involving clorazepate dipotassium?
- Active trials: None listed in ClinicalTrials.gov since 2015.
- Recent research focus: Pharmacokinetic and bioequivalence studies for generic formulations.
- Planned studies: No new Phase 1 or Phase 2 trials registered in the past five years.
- Indications under exploration: No recent exploration; existing approvals cover anxiety and seizures.
How has the market landscape for clorazepate dipotassium evolved?
Market presence and sales dynamics
| Aspect |
Data/Trend |
| Market exclusivity |
Expired for original formulations in most markets; generics dominate. |
| Market share (US, 2022) |
Estimated under $10 million in retail and hospital settings due to competition and declining use. |
| Key formulations |
Oral tablets predominant; minor oral liquids available. |
| Distribution channels |
Primarily through off-patent generic drug suppliers. |
Competitive landscape
Clorazepate dipotassium faces competitive pressure from other benzodiazepines like diazepam, lorazepam, and alprazolam, which have broader indications, longer half-lives, and more clinical trial backing. The shift to newer medications for anxiety and seizures reduces prescribing of older benzodiazepines.
What are the projections for the market over the next five years?
Market size forecast
| Year |
Estimated Market Value |
Growth Rate (CAGR) |
| 2023 |
$8 million |
-2% (declining trend) |
| 2024 |
$7.8 million |
-2.5% |
| 2025 |
$7.6 million |
-3% |
| 2026 |
$7.4 million |
-3% |
| 2027 |
$7.2 million |
-3% |
Expected decline driven by decreasing prescriptions, replacement by newer benzodiazepines and non-benzodiazepine agents.
Market driver and restraint analysis
Drivers:
- Cost advantage of generics.
- Existing FDA approvals provide stable supply routes.
Restraints:
- Decline in prescribing due to safety concerns with benzodiazepines.
- Shift toward non-benzodiazepine and non-pharmacologic therapies.
Regulatory and policy influences
- Increased FDA oversight regarding benzodiazepine prescribing practices.
- State and federal initiatives targeting opioid and benzodiazepine misuse reduce overall benzodiazepine prescriptions.
Implications for stakeholders
- Pharmaceutical companies: Limited R&D interest; focus on generics.
- Investors: Minimal growth prospects; potential market decline invites cautious positioning.
- Healthcare providers: Reduced prescribing due to safety concerns; alternative medicines preferred.
Summary
Clorazepate dipotassium's clinical development activity has ceased. It remains a small, declining market dominated by generics, with negligible growth prospects due to safety issues and competitive replacements. The product's future hinges on market shifts in benzodiazepine use, regulatory policies, and evolving treatment paradigms.
Key Takeaways
- No recent clinical trials; phase-out from development pipeline.
- Market size under $10 million; steadily declining.
- Competitive landscape dominated by newer benzodiazepines and alternative therapies.
- Projected annual decline of approximately 3% over the next five years.
- Regulatory pressures and safety concerns inhibit market expansion.
FAQs
1. Is clorazepate dipotassium still approved for any new indications?
No. Its last FDA approval was for anxiety and seizure management, with no recent indication expansions.
2. Are there ongoing efforts to develop generic formulations?
Yes. Most manufacturers have developed bioequivalent generics, maintaining market supply.
3. Will market decline continue?
Yes; driven by safety concerns and competitive drugs suppress demand further.
4. Are there any new formulations or delivery methods under development?
No recent development projects focus on alternative formulations; the focus remains on existing oral tablets.
5. Has there been regulatory push to restrict benzodiazepine use?
Yes. Several policies aim to curb benzodiazepine misuse, impacting prescribing trends for all drugs in this class.
References
[1] Food and Drug Administration (FDA). (2019). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] IMS Health. (2022). Market Insights on Benzodiazepine Prescriptions.
[3] ClinicalTrials.gov. (2023). Search results for "clorazepate dipotassium."
